Dr. Lal Pathlabs Ltd.
1,938.00+27.4 (+1.43%)
14 Oct, 12:00 AM
Stock News
Dr. Lal Pathlabs Ltd. latest news covering earnings updates, regulatory announcements, analyst actions and market-moving events.
Moneycontrol
Axis Direct bullish on Dr Lal PathLabs, Vijaya Diagnostic and Nephrocare, assigns 'Buy' ratings with up to 21% upside
Axis Direct assigned a Buy rating to Dr Lal PathLabs with a target price of Rs 2,315 versus a current price of Rs 1,934, implying 20% upside, citing its pan-India pathology network, over 70% retail B2C revenue share, zero-net-debt balance sheet and 26%-27% EBITDA margins.
12th Oct '26 7:33 am
Read full article on moneycontrol.com